Tygacil gains indication for community-acquired bacterial pneumonia in adults

Tygacil (tigecycline, from Wyeth) has been FDA approved for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by susceptible strains of indicated pathogens. This approval was based on data from two randomized, double-blind, active-controlled, multinational studies (Studies 308 and 313) that evaluated the safety and efficacy of Tygacil compared to levofloxacin in patients hospitalized with CABP. Results showed that clinical cure rates were comparable for Tygacil and levofloxacin: 90.6% and 88.9% for Tygacil and 87.2% and 85.3% for levofloxacin in Studies 308 and 313, respectively.

Tygacil is already indicated for the treatment of susceptible complicated skin and skin structure and intra-abdominal infections in adults.

For more information call (800) 934-5556 or visit www.wyeth.com.